-
Sector Analysis
Pulmonary Arterial Hypertension (PAH) Epidemiology Analysis and Forecast to 2034
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder of unknown cause, characterized by vascular proliferation and remodelling of the small pulmonary arteries. A significant number of risk factors and pathophysiological conditions are suspected to play roles in disease progression (Humbert et al., 2004, 2010; Simonneau et al., 2004; Bonnet et al., 2017). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs and can lead to right ventricular overload...
-
Product Insights
Acute Decompensated Heart Failure Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Decompensated Heart Failure - Global Clinical Trials Review, 2025" provides an overview of Acute Decompensated Heart Failure Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Decompensated Heart Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Dilated Cardiomyopathy (DCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Dilated Cardiomyopathy Therapeutics. - In 2024, more than three million diagnosed prevalent cases of DCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - The treatment of DCM is primarily focused on symptom management using beta-blockers, ACE inhibitors, ARBs, MRAs, and SGLT2 inhibitors. - Currently, 34 molecules are being developed for DCM across various stages of the pipeline. - Over the past 10...
-
Sector Analysis
Hypertrophic Cardiomyopathy (HCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypertrophic Cardiomyopathy Therapeutics. - In 2024, more than two million diagnosed prevalent cases of HCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - HCM management has traditionally relied on generic beta-blockers and calcium channel blockers to alleviate symptoms. - A total of 34 molecules are in development for HCM, including two drugs in the pre-registration stage, two drugs in Phase III, and...
-
Product Insights
Stroke Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Stroke - Global Clinical Trials Review, 2025" provides an overview of Stroke Clinical trials scenario. This report provides top line data relating to the clinical trials on Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Heart Failure in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2032
Heart Failure Market Report Overview The heart failure market size across the 68M was $21.6 billion in 2022. The “Heart Failure in 68 Markets” research report covers the 68 geographical markets and provides an Excel-based forecast model for the market through 2033. Heart Failure Market Outlook, 2022-2033 ($ Billion) Buy the Full Report for More Insights on the Heart Failure Market Report Forecast Download a Free Report Sample The Heart Failure market report contains patient-based forecast sales data for the...
-
Sector Analysis
Acute Coronary Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Acute Coronary Syndrome Marketed and Pipeline Drugs Market Overview The term acute coronary syndrome (ACS) applies to a spectrum of acute cardiovascular (CV) disease states that are precipitated by coronary artery occlusion (stenosis) resulting in ischemia (a reduction or loss of blood flow to tissue) and the necrosis (death) of myocardial tissue. In the most modern use of the term, ACS strictly refers to a range of ischemic CV events that include UA, myocardial infarction (MI), and death due to...
-
Product Insights
Ischemic Stroke - Drugs In Development, 2024
Empower your strategies with our Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic stroke occurs when there is a disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This can happen when a blood vessel that supplies blood to the brain becomes blocked or narrowed, often due to the formation of a blood clot or plaque buildup within the vessel. The blockage can occur within...
-
Product Insights
Pulmonary Hypertension - Drugs In Development, 2024
Empower your strategies with our Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen...
-
Product Insights
Pulmonary Arterial Hypertension - Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.